Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StAtins for Venous Event Reduction in Patients with Venous Thromboembolism
2021-001559-15Phase 2Active
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Symptomatic recurrent major venous thromboembolism. Started Mar 2021; status: active.
02
Drugs
rosuvastatin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)post-thrombotic syndrome (PTS)
Beyond the preview
Go deeper on 2021-001559-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001559-15.